Profil
Joshua Friedman is Senior Vice President-Clinical Development at Spyre Therapeutics, Inc. since 2023.
Formerly, Dr. Friedman was Vice President & Head-Translational Science at Spark Therapeutics, Inc. from 2022 to 2023 and Senior Director-Clinical Research at Alnylam Pharmaceuticals, Inc. from 2019 to 2022.
Education includes undergraduate studies at Harvard University and a doctorate from the University of Pennsylvania.
Postes actifs de Joshua Friedman
| Sociétés | Poste | Début |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 27/11/2023 |
Anciens postes connus de Joshua Friedman
| Sociétés | Poste | Fin |
|---|---|---|
| SPARK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2023 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2022 |
Formation de Joshua Friedman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Develops therapy products for debilitating diseases | Health Technology |
















